The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin; R) on the pharmacokinetics (PK) of Cbz.
Alain C. Mita
No relevant relationships to disclose
Albert C. Lockhart
Research Funding - Amgen; Bayer; Genentech; Lilly; Merck; Millennium; Novartis; Pfizer
James Lloyd Wade
No relevant relationships to disclose
John Charles Morris
No relevant relationships to disclose
Olivier Rixe
Research Funding - Sanofi
Jean-François Dedieu
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Claudine Wack
Employment or Leadership Position - Sanofi
Laurent Kassalow
Consultant or Advisory Role - Sanofi
John Sarantopoulos
No relevant relationships to disclose